Vitamin D Supplementation in Vitamin D Deficient Obese Children During Weight-loss Program

July 6, 2016 updated by: University Clinical Centre, Gdansk

Long-term Effects of Vitamin D Supplementation in Vitamin D Deficient Obese Children During Integrated Weight-loss Program - a Double Blind Placebo Controlled Study

  1. Analyze the influence of vitamin D supplementation in obese children during weight-loss program on BMI, body composition and bone mineral density.
  2. Analyze the influence of vitamin D supplementation on the risk profile of obesity-related complications, namely impaired tolerance of glucose, insulin resistance, dyslipidemia and arterial hypertension, in obese children participating in weight-loss program.
  3. Analyze the prevalence of vitamin D deficiency among obese children.
  4. Analyze the risk factors of vitamin D deficiency in obese children (age, gender, pubertal status).

Study Overview

Status

Unknown

Conditions

Detailed Description

The study will be conducted as a continuation and development of "6-10-14 for Health" program. The first phase of the program, financed by the municipality of Gdansk, was conducted in 2011-2013. The program comprised of screening and survey conducted among all 6-, 10- and 14-year-old children attending primary and grammar schools. A total of 18 162 children (including 7 448 6-year olds, 6 720 10-year olds and 3 994 14-year olds) were examined. A group of children with risk factors of civilization-related diseases (overweight and obesity defined according to BMI percentile charts. was identified on the basis of the screening. This group included 2 798 (16.32%) children, among them 9.17% of 6-years of age, 19.30% of 10-years and 20.48% of 14-years). All these children were qualified to intervention and education program. A total of 1 627 children qualified on the basis of screening eventually took part in the first edition of the program.

A total of 4 meetings with participating children and their caregivers were scheduled during the 12-month-long education and intervention program: at enrollment, and 3, 6 and 12 months thereafter. The meetings had form of individual consultations with various specialists. The first visit included complex medical examination, discussion on a health status of a child, interpretation of laboratory findings, and consultations with dietician, psychologist and physical education specialist. After consulting all the specialists involved in the program, individual protocol of health intervention was developed for every child. The objectives of the intervention included modification of diet, increasing health activity level and strengthening of health-seeking behaviors of child's family members. Adherence to the protocol and achieved results were evaluated during follow-up meetings with the specialists, and constituted the basis for development of individualized intervention plans for subsequent months.

The preliminary evaluation of the program effects was conducted in the group of 300 participants. The average percentile of BMI at enrollment to the program and after 12 months of participation amounted to 92.96 and 88.83, respectively. Participation in the program was reflected by a significant decrease in BMI percentile (p=0.0001), as well as by a significant drop off in fat mass content measured by bioelectrical impedance, from 39.0% to 31.4% (p=0.0001).

On the basis of these findings, the municipality of Gdansk decided to support the program for 2014-2016.

The experiment will follow a pattern of double blind randomized study. The enrolled subjects will be randomly assigned to one of the two groups:

Group 1 - weight-loss program for 52 weeks + vitamin D 1200 (IU) daily for 26 weeks Group 2 - weight-loss program for 52 weeks +placebo daily for 26 weeks

Visit I: enrollment:

  • medical history, physical examination
  • interpretation of laboratory findings (the tests conducted during screening + concentration of vitamin D),
  • anthropometric evaluation and analysis of body composition (bioimpedance method)
  • consultation of dietician, psychologist and specialist of physical activity, and defining detailed protocol of intervention
  • Kasch Pulse Recovery Test
  • determination of hs-C-reactive protein, Interleukin 6, chemerin and adiponectin concentrations in blood samples obtained during screening
  • informing parents about the objectives and protocol of the study
  • obtaining written informed consent for participation in the study
  • randomization to GROUP I or II
  • densitometry (DXA) - within one week after enrollment

Visit II: after 13 weeks:

  • medical history, physical examination
  • anthropometric evaluation and analysis of body composition (bioimpedance method)
  • consultation of dietician, psychologist and specialist of physical activity, and defining detailed protocol of intervention

Within a week prior to Visit III - obtaining blood (ca. 5 ml) for laboratory testing (complete blood count, lipid profile, hs-C-reactive protein, oral glucose tolerance test, insulin, Interleukin 6, adiponectin and chemerin concentrations

Visit III: after 26 weeks:

  • medical history, physical examination
  • interpretation of laboratory findings
  • anthropometric evaluation and analysis of body composition (bioimpedance method)
  • consultation of dietician, psychologist and specialist of physical activity, and defining detailed protocol of intervention
  • obtaining blood for laboratory testing
  • termination of active compound/placebo administration

Visit IV: after 52 weeks:

  • medical history, physical examination
  • anthropometric evaluation and analysis of body composition (bioimpedance method)
  • consultation of dietician, psychologist and specialist of physical activity, and defining detailed protocol of intervention
  • densitometry (DXA) - within one week after terminating the study

Study Type

Interventional

Enrollment (Anticipated)

200

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Pomorskie
      • Gdansk, Pomorskie, Poland, 80-210
        • Recruiting
        • IUCCGdansk
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 years to 14 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • overweight (BMI between the 85th and 95th percentile) or obesity (BMI > 95th percentile), identified on the basis of anthropometric parameters
  • blood concentration of 25(OH)D3 < 30 ng/ml
  • written consent of legal guardians

Exclusion Criteria:

  • Chronic conditions (asthma or allergies, inflammatory diseases of connective tissue, gastrointestinal disorders, diseases of kidneys and liver, disorders of bone metabolism)
  • Contraindications to administration of vitamin D
  • Administration of any preparation containing vitamin D, calcium, or steroid hormones during 3 months preceding the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Vitamin D 1200 IU
Supplementation with vitamin D (1200 IU) once a day for 26 weeks
Vitamin D 1200 IU once a day for 26 weeks
Other Names:
  • cholecalciferol
Placebo Comparator: Placebo
Placebo once a day for 26 weeks
placebo once a day for 26 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Bone mineral density
Time Frame: 12 months
Increase in bone mineral density during weight-loss program and vitamin D supplementation
12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood level of vitamin D
Time Frame: 12 months
Changes in blood level of vitamin D after supplementation
12 months
Arterial blood pressure
Time Frame: 12 months
Change in blood pressure afer weight-loss and vitamin D supplementation
12 months
Lipid profile
Time Frame: 12 months
Change of lipid profile after weight-loss and vitamin D supplementation
12 months
Oral Glucose Tolerance Test
Time Frame: 12 months
Change of biochemical parameters after weight-loss and vitamin D supplementation
12 months
Chemerin
Time Frame: 12 months
Change in chemerin level
12 months
BMI (kg/m2)
Time Frame: 12 months
Change of BMI during 12-months weight loss-program and supplementation of vitamin D
12 months
Fat mass (kg)
Time Frame: 12 months
Change in fat free mass during 12-months weight-loss programme and supplementation of vitamin D
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Agnieszka Szlagatys-Sidorkiewicz, MD, PhD, University Clinical Centre, Gdańsk

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2016

Primary Completion (Anticipated)

February 1, 2018

Study Completion (Anticipated)

February 1, 2019

Study Registration Dates

First Submitted

June 8, 2016

First Submitted That Met QC Criteria

July 6, 2016

First Posted (Estimate)

July 11, 2016

Study Record Updates

Last Update Posted (Estimate)

July 11, 2016

Last Update Submitted That Met QC Criteria

July 6, 2016

Last Verified

July 1, 2016

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on Vitamin D 1200 IU

3
Subscribe